Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Conjugate vaccine

Meningococcal ACWY vaccine

Brand names: Nimenrix, Menveo, MenQuadfi

The meningococcal ACWY vaccine is a quadrivalent conjugate vaccine providing active immunisation against Neisseria meningitidis serogroups A, C, W and Y, used in the UK adolescent programme and for certain at-risk groups and travellers.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

The capsular polysaccharides of serogroups A, C, W and Y are conjugated to a carrier protein, generating a T-cell-dependent immune response with immunological memory against these meningococcal serogroups.

Prescribing in practice

  • It does not protect against serogroup B disease, so it is not a substitute for separate meningococcal B immunisation where that is indicated.
  • It is recommended for adolescents in the UK schedule and for specific risk groups and travellers, such as those attending the Hajj, in line with current guidance.
  • Reactogenicity is generally mild, but as with any vaccine, facilities to manage rare anaphylaxis should be available.

Monitoring

Observe for immediate hypersensitivity after administration and record the dose in the immunisation record.

Counselling the patient

  • This vaccine protects against four meningococcal groups but not group B.
  • A sore arm, mild fever or headache can occur and usually settle quickly.
  • Mention recent or planned travel so any additional vaccines can be considered.

Evidence & guidelines

The UK national immunisation programme recommends meningococcal ACWY vaccination for adolescents and defined risk groups.

Reference: UK Green Book; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Drugs
Pathways